Benchmark Lowers Harvard Bioscience (NASDAQ:HBIO) Price Target to $4.50
Harvard Bioscience (NASDAQ:HBIO – Free Report) had its price objective reduced by Benchmark from $5.50 to $4.50 in a report issued on Monday morning,Benzinga reports. They currently have a speculative buy rating on the medical instruments supplier’s stock. Harvard Bioscience Price Performance Shares of NASDAQ:HBIO opened at $0.60 on Monday. Harvard Bioscience has a fifty-two […]
More Stories
703 Shares in CrowdStrike Holdings, Inc. (NASDAQ:CRWD) Acquired by OLD National Bancorp IN
OLD National Bancorp IN purchased a new position in CrowdStrike Holdings, Inc. (NASDAQ:CRWD – Free Report) during the 1st quarter,...
Barry Sanders Net Worth 2025: NFL Icon’s Financial Playbook
Renowned as one of the best running backs in NFL history, Barry Sanders has not only made an impact in...
Artificial Intelligence Revolutionizes Slot Game Development and Player Experience
Slot gaming has seen major changes over the past years, and one of the key factors that brought about this...
OLD National Bancorp IN Has $378,000 Holdings in General Motors (NYSE:GM)
OLD National Bancorp IN increased its stake in shares of General Motors (NYSE:GM – Free Report) (TSE:GMM.U) by 18.4% in...
Veralto Co. (NYSE:VLTO) Shares Acquired by Park Avenue Securities LLC
Park Avenue Securities LLC lifted its position in shares of Veralto Co. (NYSE:VLTO – Free Report) by 11.5% during the...
OLD National Bancorp IN Buys 799 Shares of Manulife Financial Co. (NYSE:MFC)
OLD National Bancorp IN boosted its position in shares of Manulife Financial Co. (NYSE:MFC – Free Report) (TSE:MFC) by 8.8%...